Clarity Wealth Advisors LLC Has $4.09 Million Stock Position in Johnson & Johnson $JNJ

Clarity Wealth Advisors LLC increased its holdings in Johnson & Johnson (NYSE:JNJ) by 3.5% during the second quarter, HoldingsChannel reports. The fund owned 26,786 shares of the company’s stock after acquiring an additional 894 shares during the quarter. Johnson & Johnson accounts for about 1.0% of Clarity Wealth Advisors LLC’s investment portfolio, making the stock its 28th biggest holding. Clarity Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $4,092,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the stock. GFG Capital LLC purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $35,000. Stone House Investment Management LLC bought a new position in Johnson & Johnson during the 1st quarter valued at $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson during the 1st quarter worth $48,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson in the 1st quarter worth $52,000. Finally, Pandora Wealth Inc. purchased a new stake in shares of Johnson & Johnson in the first quarter valued at about $65,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on JNJ. Cowen restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Barclays boosted their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. HSBC increased their price target on Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Finally, Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a research note on Monday, October 20th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $188.29 on Tuesday. The company has a market capitalization of $453.65 billion, a P/E ratio of 18.17, a P/E/G ratio of 2.19 and a beta of 0.38. The business has a fifty day simple moving average of $184.47 and a two-hundred day simple moving average of $169.03. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter. On average, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.